Rydex Biotechnology Fund Class H (RYOAX)
| Fund Assets | 136.15M |
| Expense Ratio | 1.65% |
| Min. Investment | $2,500 |
| Turnover | 79.00% |
| Dividend (ttm) | 9.41 |
| Dividend Yield | 15.79% |
| Dividend Growth | -0.18% |
| Payout Frequency | n/a |
| Ex-Dividend Date | Dec 16, 2025 |
| Previous Close | 59.06 |
| YTD Return | 2.85% |
| 1-Year Return | 29.18% |
| 5-Year Return | 10.63% |
| 52-Week Low | 38.30 |
| 52-Week High | 60.79 |
| Beta (5Y) | n/a |
| Holdings | 77 |
| Inception Date | Apr 1, 1998 |
About RYOAX
Rydex Biotechnology Fund Class H is a mutual fund designed to seek capital appreciation by investing primarily in companies within the biotechnology industry. The fund typically allocates at least 80% of its net assets to equity securities issued by biotechnology firms, which are engaged in research, development, manufacturing, and distribution of various biotechnological products and services. This focus positions the fund to capture growth opportunities in sectors such as pharmaceuticals, medical devices, and advancements in genetic engineering. Managed by Security Investors, LLC, the fund utilizes a team-managed approach and targets exposure across both established and emerging biotechnology companies. Its annual distribution frequency and active management make it a specialized vehicle for investors seeking focused access to the innovation-driven biotech market, which plays an increasingly vital role in healthcare and medical advancements. Notably, the fund maintains a higher expense ratio compared to broad market funds, reflecting the specialized expertise and research intensity required in this sector.
Performance
RYOAX had a total return of 29.18% in the past year, including dividends. Since the fund's inception, the average annual return has been 14.12%.
Equivalent Funds
These are funds that follow the same index from the other major fund companies.
| Symbol | Provider | Name | Expense Ratio |
|---|---|---|---|
| FIKCX | Fidelity | Fidelity Advisor Health Care Fund - Class Z | 0.59% |
| FSPHX | Fidelity | Fidelity Select Health Care Portfolio | 0.63% |
| FIJYX | Fidelity | Fidelity Advisor Biotechnology Fund - Class Z | 0.61% |
| FACDX | Fidelity | Fidelity Advisor Health Care Fund - Class A | 0.98% |
| FSHCX | Fidelity | Fidelity Select Health Care Services Portfolio | 0.67% |
Top 10 Holdings
36.83% of assets| Name | Symbol | Weight |
|---|---|---|
| AbbVie Inc. | ABBV | 7.53% |
| Amgen Inc. | AMGN | 4.96% |
| Gilead Sciences, Inc. | GILD | 4.49% |
| Vertex Pharmaceuticals Incorporated | VRTX | 4.41% |
| Regeneron Pharmaceuticals, Inc. | REGN | 3.65% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 2.90% |
| Insmed Incorporated | INSM | 2.32% |
| Natera, Inc. | NTRA | 2.27% |
| AstraZeneca PLC | AZN | 2.22% |
| Biogen Inc. | BIIB | 2.09% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 16, 2025 | $9.40578 | Dec 16, 2025 |
| Dec 12, 2024 | $9.42277 | Dec 12, 2024 |
| Dec 20, 2022 | $0.89943 | Dec 20, 2022 |
| Dec 8, 2021 | $15.77303 | Dec 8, 2021 |
| Dec 9, 2020 | $6.95038 | Dec 9, 2020 |
| Dec 10, 2019 | $3.60206 | Dec 10, 2019 |